Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Steve's Channelling Thread -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (21924)	7/27/2001 9:19:19 PM
From: westpacific	Respond to of 30051

CRA is one I do like, however at this price I have problems with it. The loss for one quarter is 101M, 1.66 per share. If the market melts and you can buy these at $10 a share or even less it may be interesting. But with many biotechs - due to the boom in the stock market many of these players shifted their funding to the private/public markets as government funding has dried up. The bigger question when it is all over is whom will be left standing. MYGN is my all time favorite however - due to the patent file they are building up. There are a couple of drug discovery genomics plays I really like trading under $10 right now. The problem is they may be years away with having a drug make it to FDA approval. At the same time the FDA is getting much more critical of what they sign off on. This was seen with that AVIR failure today. At the same time I think the whole bio public offering is just another big scam that will make a bunch of scientists and researchers rich while leaving the public holding the bag. These stocks are very, very high risk and should only be played by those that can read the technicals. It is charts like this I have a problem with: finance.yahoo.com The whole sector is in a massive bubble, and was just another vehicle for the scamsters on Wall Street to rip off the public. Just like Fuel Cells. West